Research programme: CD26 antigen antagonists - DARA BioSciences

Drug Profile

Research programme: CD26 antigen antagonists - DARA BioSciences

Alternative Names: DB 040; DB 160; DB 295; Dipeptidyl peptidase IV inhibitors; DPP-IV inhibitors

Latest Information Update: 17 Feb 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator DARA Biosciences
  • Developer Midatech Pharma US
  • Class Small molecules
  • Mechanism of Action CD26 antigen inhibitors; Glucagon-like peptide 1 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Type 2 diabetes mellitus

Most Recent Events

  • 15 Feb 2012 Research programme: CD26 antigen antagonists - DARA BioSciences is available for licensing as of 15 Feb 2012. http://www.darabio.com
  • 17 Jan 2012 DARA BioSciences has identified DB 160 as a preclinical candidate for future development and monetisation
  • 02 Aug 2007 Preclinical trials in Type-2 diabetes mellitus in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top